The following table lists those OA disorders that will be reported. In 1996, the Newborn Screening Program began considering a recommendation to add the 14 FOD and OA disorders listed above to the newborn screen panel. An extensive review by the Newborn Screening Advisory Group determined that, as a group, these FOD and OA disorders met Wisconsin's established criteria for screening purposes. Prevalence of the disorder must warrant screening. It is estimated that as a group these 14 disorders will have a prevalence rate greater than 1 per 10,000 live birhts.
Early detection benifits outweith adverse consequences of false positives, costs to screen, etc.
All 14 of these disorders, if untreated, have very severe medical complications as noted previously. The clinical symptoms can be prevented through a number of interventions as noted above and most importantly the realization that a fasting state can be lethal. Methodology must be adaptable to mass screening. Cost of the test must be comparable to that of other established tests. The Screening Test and Technology Detection of these 14 FOD and OA disorders can be accomplished by measuring levels of acylcarnitines in the blood spot specimens.